Adiponectin and myocardial infarction: a paradox or a paradigm?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. Once considered a disease of the affluent, obesity now prevails in the poorer developing nations as well.1 Although it is widely acknowledged that obesity, together with its allied metabolic disorders, is closely associated with the pathogenesis of cardiovascular diseases (CVDs),1,2 the precise molecular links between obesity and CVD remain speculative. It is evident that adipose tissue, traditionally viewed as a passive energy reservoir, plays a role in homeostasis and metabolism. Adipose tissue has autocrine, paracrine, and endocrine functions and synthesizes and releases a wide array of cytokine-like products collectively termed adipokines. Adipokines include pro- and anti-inflammatory molecules, complement factors, growth factors, and signalling proteins2 that modulate inflammatory, metabolic, and cardiovascular events.2 Adiponectin is an adipocyte-specific protein that circulates in concentrations greater than any other hormone in the body. In contrast to many of the other adipokines, adiponectin appears to offer cardiovascular and metabolic protection via insulin sensitizing, anti-inflammatory, lipid metabolism, anti-atherogenesis, and anti-angiogenic effects, which, in part, are mediated through adiponectin receptors.3 Adiponectin accumulates in the sub-endothelium of injured human arteries where it inhibits monocyte adhesion to endothelial cells and ultimately inhibits the migration and proliferation of vascular smooth muscle that contribute to the atherosclerotic process.4 Adiponectin levels are lower in females when compared with males, obese subjects vs. lean subjects, and type 2 diabetics vs. non-diabetics. There is a strong negative correlation between plasma adiponectin levels and visceral fat, as well as body mass index (BMI) in both humans and animals. Low levels of adiponectin are positively associated with an increased incidence and risk of obesity, diabetes mellitus, insulin resistance, low HDL, high triglycerides, and ultimately the development of vascular diseases.5 Cavusoglu et al.6 reported on a 2-year study that included 325 high-risk males with cardiac-related chest pain and underwent coronary angiography. Elevated circulating adiponectin levels at presentation were found to be independent markers of both myocardial infarction (MI) and all-cause mortality at 2 years, challenging the accumulated cellular, animal, and human epidemiological data that support adiponectin's role as a protective cardiovascular molecule. Adding to this paradox was the finding that the same inverse relationship previously reported with type 2 diabetes mellitus-related hypertension, HbA1c levels, insulin, BMI, and triglycerides5,7 was seen despite adiponectin levels paralleling cardiovascular morbidity. Only C-reactive protein (CRP),2 a recognized inflammatory factor, and adiponectin persistently and independently transpired as risk factors for MI and mortality, regardless of further statistical adjustments. A similar correlation of adiponectin levels with cardiovascular mortality was also evident in patients with congestive heart failure.8 In this study, patients with adiponectin levels in the upper two tertiles had triple the mortality risk when compared with those patients within the lowest tertile. The mortality rate was also inversely related to BMI, most probably reflecting the known association of cardiac ‘wasting’ with increased mortality, suggesting that the paradoxical increase of adiponectin levels in those with the highest mortality may have been secondary to weight loss, a known stimulator of adiponectin. Animal data support adiponectin as a cardiovascular protective molecule. In a mouse model of acute MI, adiponectin null mice responded with larger infarct sizes, greater myocardial cell apoptosis, and increased tumour necrosis factor α expression when compared with wild-type controls.9 Rescue attempts with adiponectin delivered by adenovirus, and recombinant adiponectin infusion prior to or during the ischaemia-reperfusion procedure, ameliorated all the associated damaging effects,9 suggesting that exogenous adiponectin protects the heart against ischaemic insults. Although adiponectin levels may decline acutely in the setting of an MI,10 this may, in part, reflect sequestering of adiponectin at the site of vascular injury, a hypothesis that remains to be tested. In a nested case-controlled study of the Health Professionals Follow-up Study (HPFS)7 of 18 225 male health care providers, there are convincing clinical data for a positive correlation between high baseline plasma adiponectin and diminished MI risk over a 6-year follow-up in subjects with no prior cardiovascular disease. This correlatio
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67663-5 · Cited by 2,903
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi, T., Ouchi, N., & Walsh, K. (2005) · Nature Medicine · doi:10.1038/nm1295 · Cited by 982
Adiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660
Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure
Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., & Hildebrandt, P. (2005) · Circulation · doi:10.1161/circulationaha.104.530972 · Cited by 605
Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes
Schulze, M. B., Shai, I., Rimm, E. B., Li, T., Rifai, N., & Hu, F. B. (2005) · Diabetes · doi:10.2337/diabetes.54.2.534 · Cited by 365 · cited 2×
“The diabetic sub-group of HPFS had a similar relationship of adiponectin levels to cardiovascular risk, and this association was in part mediated by higher levels of HDL.11 The plasma adiponectin levels reported by Cavusoglu et al. were within the boundaries of the lowest two HPFS quintiles, which were defined as the…”
Background
Cited by
Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736
“Interest in the direct myocardial effects of adiponectin has escalated greatly in recent years (345), and the promise of many initial studies is such that it is likely adiponectin may represent a fruitful therapeutic target in heart failure (267, 268).”
BackgroundSerum markers of inflammation and oxidative stress in sarcopenia
Can, B., Kara, O., Kizilarslanoglu, M. C., Arik, G., Aycicek, G. S., Sumer, F., Civelek, R., Demirtas, C., & Ulger, Z. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0626-2 · Cited by 176
“Although there is lack of evidence on the issue, these conflicting results might be explained by adiponectin resistance [41].”
BackgroundClark, J. E. (2012) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-11-19 · Cited by 19
“source within the body of individuals who are obese, without a concurrent rise in adiponectin levels that is seen only with increasing levels of physical activity [33,35,46,47].”
BackgroundInfluential
Metadata
- Authors
- Teoh, H.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-01
- Volume
- 27
- Issue
- 19
- Pages
- 2266-2268
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2117075530
- Cited by
- 49
- References
- 6
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adiponectin and myocardial infarction: a paradox or a paradigm? https://app.cochat.ai/papers/10.1093/eurheartj/ehl248
- The paper
- Teoh, H. (2006). Adiponectin and myocardial infarction: a paradox or a paradigm? European Heart Journal. https://doi.org/10.1093/eurheartj/ehl248
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.